|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received January 16, 2002
Accepted after revision March 20, 2002
1 Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH and Physician Scientist Training Program, Molecular and Developmental Biology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA
2 Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA
* To whom correspondence should be addressed. E-mail: molkj0{at}chmcc.org.
The heart is a dynamic organ capable of adapting its size and architecture in response to alterations in workload associated with developmental maturation, physiological stimulation and pathological diseases. Such alterations in heart size typically result from the hypertrophic growth of individual myocytes, but not myocyte cellular proliferation. In recent years, a great deal of investigation has gone toward elucidating the molecular signalling machinery that underlies the hypertrophic response and manner in which increased cardiac load promotes alterations in gene expression. To this end, the Ca2+-calmodulin-activated phosphatase calcineurin has been proposed as a necessary component of the multi-pathway hypertrophy program in the heart. Despite initial controversy over this hypothesis due to disparate results from pharmacological inhibitory studies in animal models of hypertrophy, compelling data from genetic models with calcineurin inhibition now exist. This review will summarize many of these studies and will attempt to address a number of unanswered issues. In particular, specific downstream mediators of calcineurin signalling will be discussed, as well as the need to identify calcineurin's temporal activation profile, transcriptional targets and cross-communication with other reactive signalling pathways in the heart. Finally, we will present evidence suggesting that calcineurin, as a Ca2+-responsive enzyme, may function as an internal load sensor in cardiac myocytes, matching output demands to hypertrophic growth.
This article has been cited by other articles:
![]() |
M. Cooling, P. Hunter, and E. J. Crampin Modeling Hypertrophic IP3 Transients in the Cardiac Myocyte Biophys. J., November 15, 2007; 93(10): 3421 - 3433. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Zima, D. J. Bare, G. A. Mignery, and L. A. Blatter IP3-dependent nuclear Ca2+ signalling in the mammalian heart J. Physiol., October 15, 2007; 584(2): 601 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes J. Am. Coll. Cardiol., January 30, 2007; 49(4): 491 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Koulmann, V. Novel-Chate, A. Peinnequin, R. Chapot, B. Serrurier, N. Simler, H. Richard, R. Ventura-Clapier, and X. Bigard Cyclosporin A Inhibits Hypoxia-induced Pulmonary Hypertension and Right Ventricle Hypertrophy Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 699 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, B. J. Wilkins, Y. J. Lee, H. Ichijo, and J. D. Molkentin Direct Interaction and Reciprocal Regulation between ASK1 and Calcineurin-NFAT Control Cardiomyocyte Death and Growth Mol. Cell. Biol., May 15, 2006; 26(10): 3785 - 3797. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Dai, J. Xu, and J. D. Molkentin The DnaJ-Related Factor Mrj Interacts with Nuclear Factor of Activated T Cells c3 and Mediates Transcriptional Repression through Class II Histone Deacetylase Recruitment Mol. Cell. Biol., November 15, 2005; 25(22): 9936 - 9948. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P D Wheeler-Jones Cell signalling in the cardiovascular system: an overview Heart, October 1, 2005; 91(10): 1366 - 1374. [Full Text] [PDF] |
||||
![]() |
U. Kirchhefer, H. A. Baba, P. Boknik, K. M. Breeden, N. Mavila, N. Bruchert, I. Justus, M. Matus, W. Schmitz, A. A. DePaoli-Roach, et al. Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2 Cardiovasc Res, October 1, 2005; 68(1): 98 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Scicchitano, L. Spath, A. Musaro, M. Molinaro, N. Rosenthal, C. Nervi, and S. Adamo Vasopressin-dependent Myogenic Cell Differentiation Is Mediated by Both Ca2+/Calmodulin-dependent Kinase and Calcineurin Pathways Mol. Biol. Cell, August 1, 2005; 16(8): 3632 - 3641. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lynch, L. Guo, P. Gelebart, K. Chilibeck, J. Xu, J. D. Molkentin, L. B. Agellon, and M. Michalak Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+-dependent signaling cascade J. Cell Biol., July 4, 2005; 170(1): 37 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Konhilas, U. Widegren, D. L. Allen, A. C. Paul, A. Cleary, and L. A. Leinwand Loaded wheel running and muscle adaptation in the mouse Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H455 - H465. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Skurk, Y. Izumiya, H. Maatz, P. Razeghi, I. Shiojima, M. Sandri, K. Sato, L. Zeng, S. Schiekofer, D. Pimentel, et al. The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling J. Biol. Chem., May 27, 2005; 280(21): 20814 - 20823. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nathan, I. Friehs, Y.-H. Choi, D. B. Cowan, H. Cao-Danh, F. X. McGowan, and P. J. del Nido Cyclosporin A But Not FK-506 Protects Against Dopamine-Induced Apoptosis in the Stunned Heart Ann. Thorac. Surg., May 1, 2005; 79(5): 1620 - 1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Lin, J.-L. Lin, C.-S. Lin, M.-C. Tsai, M.-J. Su, L.-P. Lai, and S. K. S. Huang Activation of the Calcineurin-Nuclear Factor of Activated T-Cell Signal Transduction Pathway in Atrial Fibrillation Chest, December 1, 2004; 126(6): 1926 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Perrier, R. Perrier, S. Richard, and J.-P. Benitah Ca2+ Controls Functional Expression of the Cardiac K+ Transient Outward Current via the Calcineurin Pathway J. Biol. Chem., September 24, 2004; 279(39): 40634 - 40639. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Isenberg Ca2+ Control of Transcription: Can We Extrapolate Signaling Cascades From Neurons to Vascular Smooth Muscle Cells? Circ. Res., May 28, 2004; 94(10): 1276 - 1278. [Full Text] [PDF] |
||||
![]() |
P. Tavi, S. Pikkarainen, J. Ronkainen, P. Niemela, M. Ilves, M. Weckstrom, O. Vuolteenaho, J. Bruton, H. Westerblad, and H. Ruskoaho Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression J. Physiol., January 15, 2004; 554(2): 309 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Wilkins, Y.-S. Dai, O. F. Bueno, S. A. Parsons, J. Xu, D. M. Plank, F. Jones, T. R. Kimball, and J. D. Molkentin Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy Circ. Res., January 9, 2004; 94(1): 110 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Zhang, S. Miyamoto, and J. H. Brown Cardiomyocyte Calcium and Calcium/Calmodulin-dependent Protein Kinase II: Friends or Foes? Recent Prog. Horm. Res., January 1, 2004; 59(1): 141 - 168. [Abstract] [Full Text] |
||||
![]() |
J. R. Keys, E. A. Greene, C. J. Cooper, S. V. Naga Prasad, H. A. Rockman, and W. J. Koch Cardiac hypertrophy and altered {beta}-adrenergic signaling in transgenic mice that express the amino terminus of {beta}-ARK1 Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2201 - H2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, P. M. Kang, and S. Izumo Phosphoinositide 3-kinase(p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy PNAS, October 14, 2003; 100(21): 12355 - 12360. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, A. Yatani, S.-J. Kim, G. Takagi, K. Irie, Q. Zhang, V. Karoor, C. Hong, G. Yang, J. Sadoshima, et al. Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy Cardiovasc Res, September 1, 2003; 59(3): 649 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mitsuhashi, N. Saito, K. Watano, K. Igarashi, S. Tagami, H. Shima, and K. Kikuchi Defect of Delta-Sarcoglycan Gene Is Responsible for Development of Dilated Cardiomyopathy of a Novel Hamster Strain, J2N-k: Calcineurin/PP2B Activity in the Heart of J2N-k Hamster J. Biochem., August 1, 2003; 134(2): 269 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. T. Pu, Q. Ma, and S. Izumo NFAT Transcription Factors Are Critical Survival Factors That Inhibit Cardiomyocyte Apoptosis During Phenylephrine Stimulation In Vitro Circ. Res., April 18, 2003; 92(7): 725 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Houser and K. B. Margulies Is Depressed Myocyte Contractility Centrally Involved in Heart Failure? Circ. Res., March 7, 2003; 92(4): 350 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Sussman, A. McCulloch, and T. K. Borg Dance Band on the Titanic: Biomechanical Signaling in Cardiac Hypertrophy Circ. Res., November 15, 2002; 91(10): 888 - 898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |